MAIA Biotechnology Reports Promising Phase 2 Trial Results for Ateganosine in Treating Resistant Non-Small Cell Lung Cancer

Reuters

2025/06/05

MAIA Biotechnology Reports Promising Phase 2 Trial Results for Ateganosine in Treating Resistant Non-Small Cell Lung Cancer

MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company, has announced positive results from its Phase 2 THIO-101 clinical trial. The trial evaluated the efficacy of their lead clinical candidate, ateganosine (THIO), in combination with Regeneron's immune checkpoint inhibitor cemiplimab (Libtayo®) for patients with advanced non-small cell lung cancer (NSCLC) resistant to prior therapies. The latest data reveals a median overall survival $(OS)$ of 17.8 months for patients receiving at least one dose of ateganosine, significantly outperforming the typical 5 to 6 months OS seen in standard-of-care chemotherapy for similar cases. These findings suggest that ateganosine may considerably impact the NSCLC treatment landscape, with potential for accelerated FDA approval and exclusivity. The treatment has been generally well-tolerated in this heavily pre-treated patient population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250605644171) on June 05, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2541020330"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541020330\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541020330?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541020330","market":"us","top_or_hot":-1,"title":"MAIA Biotechnology Reports Promising Phase 2 Trial Results for Ateganosine in Treating Resistant Non-Small Cell Lung Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MAIA Biotechnology Reports Promising Phase 2 Trial Results for Ateganosine in Treating Resistant Non-Small Cell Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company, has announced positive results from its Phase 2 THIO-101 clinical trial. The trial evaluated the efficacy of their lead clinical candidate, ateganosine (THIO), in combination with Regeneron's immune checkpoint inhibitor cemiplimab (Libtayo®) for patients with advanced non-small cell lung cancer (NSCLC) resistant to prior therapies. The latest data reveals a median overall survival <a href=\"https://laohu8.com/S/OS\">$(OS)$</a> of 17.8 months for patients receiving at least one dose of ateganosine, significantly outperforming the typical 5 to 6 months OS seen in standard-of-care chemotherapy for similar cases. These findings suggest that ateganosine may considerably impact the NSCLC treatment landscape, with potential for accelerated FDA approval and exclusivity. The treatment has been generally well-tolerated in this heavily pre-treated patient population.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250605644171) on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MAIA Biotechnology Reports Promising Phase 2 Trial Results for Ateganosine in Treating Resistant Non-Small Cell Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMAIA Biotechnology Reports Promising Phase 2 Trial Results for Ateganosine in Treating Resistant Non-Small Cell Lung Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-05 20:04</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MAIA Biotechnology Reports Promising Phase 2 Trial Results for Ateganosine in Treating Resistant Non-Small Cell Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company, has announced positive results from its Phase 2 THIO-101 clinical trial. The trial evaluated the efficacy of their lead clinical candidate, ateganosine (THIO), in combination with Regeneron's immune checkpoint inhibitor cemiplimab (Libtayo®) for patients with advanced non-small cell lung cancer (NSCLC) resistant to prior therapies. The latest data reveals a median overall survival <a href=\"https://laohu8.com/S/OS\">$(OS)$</a> of 17.8 months for patients receiving at least one dose of ateganosine, significantly outperforming the typical 5 to 6 months OS seen in standard-of-care chemotherapy for similar cases. These findings suggest that ateganosine may considerably impact the NSCLC treatment landscape, with potential for accelerated FDA approval and exclusivity. The treatment has been generally well-tolerated in this heavily pre-treated patient population.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250605644171) on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0823434583.USD","symbol_name":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDLVbGLY:1","article_id":"2541020330","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541020330","pubTimestamp":1749125057,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company, has announced positive results from its Phase 2 THIO-101 clinical trial. The trial evaluated the efficacy of their lead clinical candidate, ateganosine , in combination with Regeneron's immune checkpoint inhibitor cemiplimab  for patients with advanced non-small cell lung cancer  resistant to prior therapies. The latest data reveals a median overall survival  of 17.8 months for patients receiving at least one dose of ateganosine, significantly outperforming the typical 5 to 6 months OS seen in standard-of-care chemotherapy for similar cases. These findings suggest that ateganosine may considerably impact the NSCLC treatment landscape, with potential for accelerated FDA approval and exclusivity. The treatment has been generally well-tolerated in this heavily pre-treated patient population.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元","LU0058720904.USD":"联博国际健康护理基金A","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","REGN":"再生元制药公司","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4139":"生物科技","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","MAIA":"MAIA Biotechnology Inc.","BK4588":"碎股","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC"},"translate_title":"MAIA Biotechnology报告了Ateganosine治疗耐药非小细胞肺癌的有希望的2期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":0.9,"MAIA":0.9},"content_text":"MAIA Biotechnology Reports Promising Phase 2 Trial Results for Ateganosine in Treating Resistant Non-Small Cell Lung Cancer\n    \n\n        MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical company, has announced positive results from its Phase 2 THIO-101 clinical trial. The trial evaluated the efficacy of their lead clinical candidate, ateganosine (THIO), in combination with Regeneron's immune checkpoint inhibitor cemiplimab (Libtayo®) for patients with advanced non-small cell lung cancer (NSCLC) resistant to prior therapies. The latest data reveals a median overall survival $(OS)$ of 17.8 months for patients receiving at least one dose of ateganosine, significantly outperforming the typical 5 to 6 months OS seen in standard-of-care chemotherapy for similar cases. These findings suggest that ateganosine may considerably impact the NSCLC treatment landscape, with potential for accelerated FDA approval and exclusivity. The treatment has been generally well-tolerated in this heavily pre-treated patient population.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250605644171) on June 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}